- Home
- OBE vs IMMP Comparison
OBE vs IMMP Comparison
Compare OBE & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- IMMP
- Stock Information
- Founded
- OBE 1979
- IMMP 1987
- Country
- OBE Canada
- IMMP Australia
- Employees
- OBE N/A
- IMMP N/A
- Industry
- OBE Oil & Gas Production
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- OBE Energy
- IMMP Health Care
- Exchange
- OBE Nasdaq
- IMMP Nasdaq
- Market Cap
- OBE 372.4M
- IMMP 304.0M
- IPO Year
- OBE N/A
- IMMP N/A
- Fundamental
- Price
- OBE $5.06
- IMMP $2.03
- Analyst Decision
- OBE Strong Buy
- IMMP Buy
- Analyst Count
- OBE 1
- IMMP 2
- Target Price
- OBE $14.00
- IMMP $8.50
- AVG Volume (30 Days)
- OBE 453.2K
- IMMP 159.0K
- Earning Date
- OBE 02-20-2025
- IMMP 01-03-2025
- Dividend Yield
- OBE N/A
- IMMP N/A
- EPS Growth
- OBE N/A
- IMMP N/A
- EPS
- OBE 1.05
- IMMP N/A
- Revenue
- OBE $516,155,298.00
- IMMP $2,563,302.00
- Revenue This Year
- OBE $23.29
- IMMP N/A
- Revenue Next Year
- OBE $12.10
- IMMP $10.84
- P/E Ratio
- OBE $4.34
- IMMP N/A
- Revenue Growth
- OBE 3.06
- IMMP 9.59
- 52 Week Low
- OBE $4.87
- IMMP $1.66
- 52 Week High
- OBE $9.07
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- OBE 37.55
- IMMP 47.96
- Support Level
- OBE $4.95
- IMMP $2.00
- Resistance Level
- OBE $5.24
- IMMP $2.24
- Average True Range (ATR)
- OBE 0.21
- IMMP 0.13
- MACD
- OBE -0.05
- IMMP -0.01
- Stochastic Oscillator
- OBE 21.02
- IMMP 25.00
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.